This ensured that on major decisions, Wu Ting and the Jin Pharmaceutical Group combined would hold an absolute majority, allowing them to have the final say on any company matter!
Wu Ting was also in full agreement with this arrangement.
After the company was registered and initially established, the Jin Pharmaceutical Group injected the first round of funding—20 million yuan in full—into the company account as start-up capital.
At the same time, Deng Feifei began recruiting the company's first batch of employees. The initial management team was seconded from the Jin Pharmaceutical Group.
Under Deng Feifei's management, Wu's Pharmaceutical Company gradually began to get up and running.
Deng Feifei and Wu Ting discussed and agreed that since the third and fourth stages of the radical cure for hepatitis B-related primary liver cancer required long-term R&D and investment, it would be treated as a long-cycle project for the company, receiving continuous funding.
